Allogeneic Alternatives to Autologous Bone Marrow: The MSC Combined Cell Strategies

Research output: Chapter in Book/Report/Conference proceedingChapter


The successful application of autologous and allogeneic stem cell therapy for heart disease has prompted more recent preclinical, and a few clinical, studies examining the safety and efficacy of combining two different types of stem cells. In virtually all instances, the combination worked better at reducing scar size and/or improving cardiac function than either cell type alone providing impetus for using two cell types together as a novel therapeutic strategy. This success is moving the field closer to combination therapy clinical trials, the first of which will examine a mix of mesenchymal and cardiac stem cells.

Original languageEnglish (US)
Title of host publicationStem Cell and Gene Therapy for Cardiovascular Disease
PublisherElsevier Science Ltd.
Number of pages12
ISBN (Electronic)9780128018637
ISBN (Print)9780128018880
StatePublished - Jan 1 2015


  • Allogeneic
  • Cardiac stem cells
  • Combination therapy
  • Mesenchymal stem cells
  • Myocardial infarction

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Allogeneic Alternatives to Autologous Bone Marrow: The MSC Combined Cell Strategies'. Together they form a unique fingerprint.

Cite this